ARTICLE | Clinical News
Alagebrium: Phase II delayed
February 28, 2005 8:00 AM UTC
ALT halted enrollment in a open-label Phase II trial due to preclinical toxicity in rats (see BioCentury, Jan. 3). The trial will continue in the patients already enrolled. Additional preclinical data...